Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?
Annemans
Lieven
L
Department of Public Health, Ghent University, and HEDM, IMS HEALTH, Brussels, Belgium. LAnnemans@be.imshealth.com
D014150:Antipsychotic Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D018803:Models, Economic; D018967:Risperidone / Q000191:economics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics*
D014150:Antipsychotic Agents; D018967:Risperidone